ADMA Biologics (ADMA) Stock Rating Lowered by BidaskClub

ADMA Biologics (NASDAQ:ADMA) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

Other research analysts have also issued research reports about the company. Maxim Group set a $10.00 target price on ADMA Biologics and gave the company a “buy” rating in a research report on Monday, May 14th. Oppenheimer set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a report on Monday. Chardan Capital initiated coverage on ADMA Biologics in a report on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective on the stock. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Finally, LADENBURG THALM/SH SH decreased their price objective on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday, June 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $9.50.

Shares of NASDAQ:ADMA opened at $5.52 on Wednesday. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $6.86. The company has a market cap of $279.61 million, a PE ratio of -2.89 and a beta of 2.40. The company has a debt-to-equity ratio of 1.76, a quick ratio of 3.60 and a current ratio of 4.92.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Monday, May 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.08). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 112.98%. The business had revenue of $4.04 million for the quarter, compared to analysts’ expectations of $7.47 million. sell-side analysts expect that ADMA Biologics will post -1.31 EPS for the current fiscal year.

In other news, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction on Friday, June 8th. The shares were bought at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the acquisition, the chief executive officer now owns 32,527 shares of the company’s stock, valued at approximately $155,479.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction on Friday, June 8th. The stock was purchased at an average price of $4.78 per share, for a total transaction of $100,002.38. Following the acquisition, the director now directly owns 98,007 shares in the company, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Insiders acquired a total of 78,222 shares of company stock worth $373,901 in the last 90 days. 16.90% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in ADMA. BlackRock Inc. lifted its holdings in ADMA Biologics by 2,295.0% in the 2nd quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock valued at $4,378,000 after purchasing an additional 930,303 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $3,751,000. Millennium Management LLC raised its holdings in shares of ADMA Biologics by 305.2% during the 1st quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock worth $1,259,000 after acquiring an additional 206,088 shares during the period. Geode Capital Management LLC raised its holdings in shares of ADMA Biologics by 420.3% during the 4th quarter. Geode Capital Management LLC now owns 112,000 shares of the biotechnology company’s stock worth $359,000 after acquiring an additional 90,474 shares during the period. Finally, Ardsley Advisory Partners purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $361,000. Institutional investors own 37.62% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Stock Symbol

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply